Hospital
Newport Hospital
Newport Hospital was paid $15.82M by Medicaid between Jan 2018 and Dec 2024, across 147 billing codes. Its largest line is 99285, emergency room visit (most serious) — 9.3% of everything it billed.
33Billing provider infoNEWPORT HOSPITAL
NEWPORT, RI 02840
NEWPORT, RI 02840
33aNPI1457346413assigned 09/15/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.82M
24GClaims125,992
24DCodes billed147
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Rhode Island
Rank by total paid#5 of 11
Median peer was paid$12.56M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MARKELL, PETER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,050 | $2.64M | |
| 2019 | 35,247 | $4.68M | |
| 2020 | 10,184 | $1.34M | |
| 2021 | 13,714 | $1.56M | |
| 2022 | 14,718 | $1.85M | |
| 2023 | 15,002 | $2.17M | |
| 2024incomplete | 10,077 | $1.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.3% | 3,120 | 2,484 | $1.46M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.1% | 10,638 | 2,882 | $1.13M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.7% | 4,516 | 3,779 | $1.06M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.8% | 5,115 | 4,088 | $918K |
| 80053 | Comprehensive metabolic panel | 4.5% | 5,029 | 3,790 | $704K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.1% | 8,611 | 6,131 | $642K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 762 | 597 | $440K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.6% | 2,452 | 2,108 | $419K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.5% | 3,533 | 2,740 | $403K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.2% | 1,607 | 1,258 | $351K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 1,693 | 1,192 | $330K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.0% | 3,711 | 1,196 | $311K |
135 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 2,621 | $267K |
| 82248 | 1.7% | 2,654 | $266K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 1,756 | $251K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 1,188 | $222K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 2,668 | $217K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.3% | 896 | $207K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.2% | 1,804 | $188K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.1% | 2,620 | $181K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.1% | 957 | $181K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 2,039 | $174K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 2,028 | $173K |
| 81003 | 1.1% | 1,948 | $170K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 972 | $167K |
| 80061 | Lipid panel | 1.0% | 2,501 | $165K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 1,016 | $161K |
| 83690 | 1.0% | 1,396 | $160K | |
| 84484 | <1% | 1,712 | $155K | |
| G0378 | Hospital observation service, per hour | <1% | 331 | $144K |
| 85027 | <1% | 2,992 | $144K | |
| 80050 | General health panel | <1% | 567 | $135K |
| 82948 | <1% | 588 | $133K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 920 | $126K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 888 | $125K |
| 83735 | <1% | 1,143 | $123K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 579 | $122K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 390 | $117K |
| 76830 | Ultrasound, transvaginal | <1% | 514 | $114K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,127 | $111K |
| 85610 | <1% | 1,379 | $110K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 694 | $107K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,827 | $106K |
| 81001 | <1% | 1,333 | $99K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 560 | $90K |
| 87481 | <1% | 596 | $85K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,947 | $82K |
| 81514 | <1% | 186 | $81K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 337 | $80K |
| 86850 | <1% | 759 | $79K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 363 | $78K |
| 97161 | <1% | 698 | $78K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 649 | $77K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,796 | $76K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 51 | $71K |
| 96376 | <1% | 289 | $70K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 80 | $69K |
| 86900 | <1% | 766 | $66K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,648 | $61K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,247 | $59K |
| 86901 | <1% | 766 | $59K | |
| 86803 | <1% | 702 | $58K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 589 | $58K |
| J2704 | Injection, propofol, 10 mg | <1% | 385 | $54K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 478 | $53K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 239 | $50K |
| 86780 | <1% | 679 | $48K | |
| J3490 | Unclassified drugs | <1% | 269 | $48K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 744 | $46K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 52 | $44K |
| 76642 | <1% | 240 | $41K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 292 | $40K |
| 87340 | <1% | 548 | $40K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 366 | $39K |
| 76801 | <1% | 122 | $37K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 147 | $32K |
| 87081 | <1% | 225 | $26K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 43 | $22K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 38 | $22K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 30 | $21K |
| 85651 | <1% | 499 | $19K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 222 | $19K |
| 82728 | <1% | 217 | $19K | |
| 82607 | <1% | 290 | $19K | |
| 84703 | <1% | 193 | $18K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 102 | $18K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 290 | $17K |
| 87088 | <1% | 413 | $17K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 229 | $17K |
| 87480 | <1% | 226 | $16K | |
| 80076 | <1% | 146 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 162 | $15K |
| 73030 | <1% | 160 | $14K | |
| 73562 | <1% | 201 | $14K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 99 | $12K |
| 72100 | <1% | 92 | $11K | |
| 86787 | <1% | 121 | $11K | |
| 83605 | <1% | 93 | $11K | |
| 82565 | <1% | 591 | $10K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 73 | $10K |
| 83540 | <1% | 167 | $10K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 55 | $10K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 46 | $10K |
| 81025 | <1% | 138 | $9K | |
| 83550 | <1% | 93 | $9K | |
| 87186 | <1% | 87 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 115 | $8K |
| 83880 | <1% | 54 | $8K | |
| 87510 | <1% | 226 | $7K | |
| 87660 | <1% | 226 | $7K | |
| 86762 | <1% | 122 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 50 | $7K |
| 84100 | <1% | 120 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 44 | $6K |
| 86140 | <1% | 118 | $6K | |
| 84702 | <1% | 47 | $6K | |
| 72141 | <1% | 13 | $6K | |
| 84439 | <1% | 117 | $6K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 29 | $5K |
| 73560 | <1% | 69 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 24 | $3K |
| 73502 | <1% | 52 | $3K | |
| 97162 | <1% | 42 | $3K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 14 | $3K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 15 | $2K |
| 84520 | <1% | 172 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 28 | $2K |
| 84481 | <1% | 25 | $2K | |
| 73630 | <1% | 19 | $1K | |
| 82105 | <1% | 25 | $1K | |
| 85379 | <1% | 17 | $1K | |
| 82947 | <1% | 41 | $1K | |
| 87077 | <1% | 35 | $1K | |
| 84460 | <1% | 32 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 51 | $1K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 62 | $1K |
| 84450 | <1% | 29 | $1K | |
| 80051 | <1% | 27 | $994.63 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 15 | $755.50 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 20 | $739.73 |
| 85730 | <1% | 24 | $676.11 | |
| 87070 | <1% | 18 | $490.86 | |
| 87205 | <1% | 19 | $414.41 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 17 | $349.05 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 21 | $346.35 |
| 82950 | <1% | 12 | $303.66 | |
| 82310 | <1% | 20 | $273.83 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARKELL, PETER (E VP & CFO)
Parent organizationLIFESPAN CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Rhode Island Hospital | Providence, RI | $380.77M |
| The Miriam Hospital | Providence, RI | $138.58M |
| Gateway Healthcare INC | Pawtucket, RI | $122.93M |
| Emma Pendleton Bradley Hospital | Riverside, RI | $37.64M |
| Rhode Island Hospital | Providence, RI | $13.22M |
| Lifespan Physician Group, INC. | Warwick, RI | $6.48M |
| Lifespan Physician Group, INC. | Providence, RI | $5.64M |
| Rhode Island Hospital | Providence, RI | $5.32M |
| Emma Pendleton Bradley Hospital | East Providence, RI | $5.03M |
| Lifespan Physician Group INC | Providence, RI | $4.41M |
| Rhode Island Hospital | Providence, RI | $3.97M |
| Newport Hospital | Newport, RI | $3.05M |
| Rhode Island Hospital | East Providence, RI | $2.58M |
| Vna Technicare, INC. | Providence, RI | $2.52M |
| Rhode Island Hospital | Providence, RI | $2.33M |
| Coastal Medical Physicians, INC. | Providence, RI | $1.33M |
| Gateway Healthcare, INC. | Pawtucket, RI | $1.31M |
| Coastal Medical Physicians, INC. | Providence, RI | $1.20M |
| Gateway Healthcare, INC | Johnston, RI | $1.13M |
| Gateway Healthcare, INC | Charlestown, RI | $731K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.